Premium
Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in‐between
Author(s) -
Passaro Antonio,
Malapelle Umberto,
Attili Ilaria,
Marinis Filippo
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32810
Subject(s) - osimertinib , medicine , lung cancer , cornerstone , identification (biology) , tyrosine kinase , resistance (ecology) , cancer , intensive care medicine , cancer research , adenocarcinoma , receptor , biology , ros1 , ecology , art , botany , visual arts
The identification of resistance mechanisms to third‐generation tyrosine kinase inhibitors—in particular osimertinib—should be considered as a cornerstone for understanding treatment individualization in an era of precision medicine, potentially improving patient outcomes significantly through a multifactorial strategy.